The agency compiled the evolving list by drawing on information from drug labeling and the published literature and is asking stakeholders to provide feedback.
Quest and LabCorp recently highlighted increased compensation costs while other industry observers have seen salaries rising for specialties like molecular.
The company's Curian immunoassay instrument is currently in front of the FDA, and the PediaStat will likely be submitted later this year.
The agreement will bring Exalenz's BreathID Breath Test Systems, a urea breath test platform for H. pylori detection, into Meridian's portfolio.
The program aims to consent up to 150,000 patients to a larger biobank program and return selective preemptive PGx results through their medical center physicians.
Genetron will provide clinical trial genomic testing and companion diagnostic development services for InnoCare's biomarker-driven oncology drug development.
Diagnostics revenues for the fourth quarter were $1.76 billion, up 4 percent from $1.69 billion in the same quarter last year.